Reshape Lifesciences Inc (RSLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2018 | 06-2018 | 03-2018 | 12-2017 | 09-2017 | |
| Sales | 8 | 10 | 139 | 76 | 360 |
| Cost of Goods | 23 | 3 | 60 | 35 | 215 |
| Gross Profit | -15 | 7 | 79 | 41 | 146 |
| Operating Expenses | 5,303 | 20,388 | 8,896 | 8,653 | 5,920 |
| Operating Income | -5,295 | -20,378 | -8,757 | -8,577 | -5,560 |
| Interest Expense | 1 | 1 | 1 | 0 | 0 |
| Other Income | 9 | -142 | -1 | -1 | -4,434 |
| Pre-tax Income | -5,287 | -20,521 | -8,759 | -8,578 | -9,994 |
| Income Tax | -531 | -1,209 | -1,382 | N/A | N/A |
| Net Income Continuous | -4,756 | -19,312 | -7,377 | -6,264 | -9,994 |
| Net Income Discontinuous | -2,249 | -15,939 | -3,856 | N/A | N/A |
| Net Income | $-7,005 | $-35,251 | $-11,233 | $-9,617 | $-9,994 |
| EPS Basic Total Ops | -3,295.01 | -266,071.10 | -91,803.61 | -277,119.20 | -266,974.70 |
| EPS Basic Continuous Ops | -2,256.69 | -157,588.00 | -60,289.16 | -200,188.60 | -266,975.00 |
| EPS Basic Discontinuous Ops | -1,038.32 | -108,483.10 | -31,514.46 | N/A | N/A |
| EPS Diluted Total Ops | -3,295.01 | -266,071.10 | -91,803.61 | -277,119.20 | -266,974.70 |
| EPS Diluted Continuous Ops | -2,256.69 | -157,588.00 | -60,289.16 | -200,188.60 | -266,975.00 |
| EPS Diluted Discontinuous Ops | -1,038.32 | -108,483.10 | -31,514.46 | N/A | N/A |
| EBITDA(a) | $-5,196 | $-6,269 | $-8,649 | $-8,468 | $-5,470 |